Get the Stockscreener App
24.21
0.88%
0.21
After Hours:
24.40
0.19
+0.78%
Tonix Pharmaceuticals Holding Corp stock is traded at $24.21, with a volume of 948.02K.
It is up +0.88% in the last 24 hours and down -28.82% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$24.00
Open:
$24.04
24h Volume:
948.02K
Relative Volume:
0.66
Market Cap:
$212.22M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-2.1501
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
-6.88%
1M Performance:
-28.82%
6M Performance:
-15.82%
1Y Performance:
+77.23%
1-Day Range:
$23.76
$24.78
1-Week Range:
$23.60
$27.33
52-Week Range:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
24.21 | 210.38M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.74 | 97.91B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.90 | 58.88B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.40 | 58.93B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
711.62 | 43.52B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
326.06 | 36.11B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
13,670 Shares in Tonix Pharmaceuticals Holding Corp. $TNXP Purchased by Rhumbline Advisers - MarketBeat
Tonix advances TNX-102 SL for depression after positive FDA meeting boosts development path - Proactive financial news
What is Zacks Small Cap's Estimate for TNXP FY2025 Earnings? - MarketBeat
Tonix Pharma Licenses Rights to Lyme Disease Antibody - MSN
Daily Brief Health Care: Shandong Weigao Blood Purification Products, TYK Medicines, Butong Group, Alteogen Inc, SBC Medical Group Holdings , Achieve Life Sciences , Tonix Pharmaceuticals Holding and more - Smartkarma
Tonix gains global rights to TNX-4800, developing one-dose seasonal protection for Lyme disease - Proactive financial news
TNXP: Tonmya™ Approved by FDA… - Zacks Small Cap Research
Tonix Pharmaceuticals Holding Corp.(NasdaqCM: TNXP) added to S&P Global BMI Index - MarketScreener
Tonix plans IND filing for depression treatment after FDA meeting By Investing.com - Investing.com Nigeria
Analyst Downgrade: Is now the right time to enter Tonix Pharmaceuticals Holding CorpWeekly Risk Report & Low Drawdown Investment Strategies - خودرو بانک
Tonix plans IND filing for depression treatment after FDA meeting - Investing.com India
Tonix Pharma Completes FDA Meeting for TNX-102 SL - TipRanks
Fed Watch: Can LeddarTech Holdings Inc Equity Warrant navigate macro headwindsQuarterly Risk Review & Low Risk Entry Point Tips - خودرو بانک
Tonix Pharmaceuticals (TNXP) Advances Toward New Depression Trea - GuruFocus
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder - The Manila Times
Tonix Pharmaceuticals Announces Plans for IND Filing of TNX-102 SL for Major Depressive Disorder Following Positive FDA Pre-IND Meeting - Quiver Quantitative
Tonix reports positive pre-IND FDA meeting for TNX-102 SL in major depressive disorder treatment - MarketScreener
Tonix Reports Positive Pre-IND FDA Meeting for TNX-102 SL in Major Depressive Disorder Treatment - TradingView
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting - GlobeNewswire
FDA-Approved Fibromyalgia Drug TNX-102 SL Shows Promise for Major Depression Treatment - Stock Titan
Revolutionary 1-shot Lyme disease prevention approved - Rolling Out
Tonix Pharmaceuticals (TNXP) Gains on Lyme Disease Treatment Lic - GuruFocus
Tonix licenses monoclonal antibody for Lyme disease prevention By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals gets global rights to Lyme disease treatment - Seeking Alpha
Tonix Pharmaceuticals (TNXP) Secures Rights to Potential Lyme Di - GuruFocus
Tonix Pharmaceuticals Secures Rights to Lyme Disease Prevention Candidate - MarketScreener
Tonix Pharmaceuticals announces in-licensing of worldwide rights to TNX-4800 - TipRanks
Tonix licenses monoclonal antibody for Lyme disease prevention - Investing.com
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800) - The Manila Times
Tonix Pharmaceuticals In-Licenses TNX-4800 for Lyme Disease Prevention Following Positive Phase 1 Study Results - Quiver Quantitative
Tonix Pharmaceuticals Announces In-licensing Phase - GlobeNewswire
70M Americans Could Benefit: Tonix's New Once-Yearly Antibody Shows Promise in Preventing Lyme Disease - Stock Titan
UMass Chan licenses monoclonal antibody for seasonal prevention of Lyme disease to Tonix Pharmaceuticals - UMass Chan Medical School
Is Tonix Pharmaceuticals Holding Corp stock risky to hold nowLayoff News & Safe Capital Investment Plans - خودرو بانک
Pattern recognition hints at Tonix Pharmaceuticals Holding Corp. upsideJuly 2025 EndofMonth & Intraday High Probability Alerts - newser.com
Investment Recap: Will Tonix Pharmaceuticals Holding Corp announce a stock splitPortfolio Value Summary & Verified Entry Point Detection - خودرو بانک
Aug Fed Impact: What are analysts price targets for Tonix Pharmaceuticals Holding CorpMarket Performance Recap & High Conviction Trade Alerts - خودرو بانک
What’s the RSI of Tonix Pharmaceuticals Holding Corp. stockMarket Risk Report & Momentum Based Trading Ideas - خودرو بانک
Sell Signal: Is Tonix Pharmaceuticals Holding Corp. exposed to currency risksWeekly Market Outlook & Accurate Trade Setup Notifications - khodrobank.com
Bull Bear: Does Tonix Pharmaceuticals Holding Corp offer margin of safetyRisk Management & Technical Confirmation Trade Alerts - خودرو بانک
Published on: 2025-09-15 21:26:59 - خودرو بانک
Aug EndMonth: Will Tonix Pharmaceuticals Holding Corp stock benefit from M ADividend Hike & Stepwise Entry/Exit Trade Alerts - خودرو بانک
Tonix showcases Phase 3 data for FDA-approved Tonmya at PAINWEEK 2025, eyes launch next quarter - Proactive financial news
Tonix Pharmaceuticals : September 2025 Investor Deck - MarketScreener
Published on: 2025-09-08 16:12:23 - beatles.ru
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the - GuruFocus
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025 - Yahoo Finance
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared Last Week - MSN
Combining machine learning predictions for Tonix Pharmaceuticals Holding Corp.Wall Street Watch & Safe Capital Growth Tips - Newser
Is Tonix Pharmaceuticals Holding Corp. stock entering bullish territoryJuly 2025 Review & AI Optimized Trade Strategies - Newser
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Treco James | Director |
Aug 20 '25 |
Buy |
36.00 |
250 |
9,000 |
250 |
| LEDERMAN SETH | Chief Executive Officer |
May 15 '25 |
Buy |
21.55 |
4,000 |
86,200 |
4,005 |
3.41%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):